Core Insights - Guardant Health's stock is experiencing an increase following the FDA's Breakthrough Device designation for its Shield multi-cancer detection test [1] - The Shield MCD test is designed for multi-cancer screening in individuals aged 45 or older at average risk, targeting various cancer types [1] Clinical Validation - At the 2025 ASCO Annual Meeting, Guardant presented data showing the Shield MCD test's high specificity and clinically meaningful sensitivity across multiple tumor types [2] - The test demonstrated 98.6% specificity and 75% sensitivity for detecting bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancers, with a cancer signal origin accuracy of 92% [3] NCCN Guidelines Update - The National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer screening guidelines, recommending testing every three years [4] - The NCCN's guideline update references the ECLIPSE study, which showed the Shield test's effectiveness in detecting colorectal cancer with a sensitivity of 83% [5] Stock Performance - Following these developments, Guardant Health's stock price rose by 10.4%, reaching $46.49 [5]